Therapeutic results of a novel enzyme-targeting radiosensitization
treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II,
in patients with stage I primary breast cancer.
Aoyama N, Ogawa Y, Yasuoka M, Ohgi K, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Miyamura M,
Yamagami T.
Oncol Lett. 2017 Jun;13(6):4741–4747. doi: 10.3892/ol.2017.6074. Epub
2017 Apr 21.
PMID: 28599475 Free PMC Article
Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol…
Linac-based stereotactic radiotherapy has little effect on the majority of advanced neoplasms. Therefore, the novel…www.ncbi.nlm.nih.gov
Therapeutic response for a novel enzyme-targeting radiosensitization
treatment (KORTUC II) for residual lesions in patients with stage IV
primary breast cancer, following induction chemotherapy with epirubicin
and cyclophosphamide or taxane.
Aoyama N, Ogawa Y, Yasuoka M, Iwasa H, Miyatake K, Yoshimatsu R,
Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Yamagami T,
Miyamura M.
Oncol Lett. 2017 Jan;13(1):69–76. doi: 10.3892/ol.2016.5456. Epub 2016
Dec 1.
PMID: 28123524 Free PMC Article
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for…
KORTUC II formulation Hyaluronic acid preparation (2.5 ml) with 1% w/v sodium hyaluronate (ARTZ Dispo ®; Seikagaku…www.ncbi.nlm.nih.gov